Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 127, Issue 21
May 26 2016
Issue Cover

Table of Contents

BLOOD FLASHBACK

Tanaka KR, Valentine WN, Miwa S. Pyruvate kinase (PK) deficiency hereditary nonspherocytic hemolytic anemia. Blood. 1962;19(3):267-295.
View Articletitled, Tanaka KR, Valentine WN, Miwa S. Pyruvate kinase (PK) deficiency hereditary nonspherocytic hemolytic anemia. <em>Blood</em>. 1962;19(3):<span class="related-article">267-295</span>.

INSIDE BLOOD COMMENTARIES

INSIDE BLOOD COMMENTARY
Knock-in editing: it functionally corrects!
Matthew H. Porteus
View Articletitled, Knock-in editing: it functionally corrects!
INSIDE BLOOD COMMENTARY
Virus fuels NK cell killing of leukemia
Steve H. Thorne
View Articletitled, Virus fuels NK cell killing of leukemia
INSIDE BLOOD COMMENTARY
Mouse models of venous thrombosis are not equal
Nigel Mackman
View Articletitled, Mouse models of venous thrombosis are not equal

PLENARY PAPER

GENE THERAPY
Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome
Nicholas Hubbard,David Hagin,Karen Sommer,Yumei Song,Iram Khan,Courtnee Clough,Hans D. Ochs,David J. Rawlings,Andrew M. Scharenberg,Troy R. Torgerson
View Articletitled, Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome
Supplemental data

PERSPECTIVES

Welcoming a new age for gene therapy in hematology
Mitchell J. Weiss,Charles G. Mullighan
View Articletitled, Welcoming a new age for gene therapy in hematology

REVIEW SERIES

A genome editing primer for the hematologist
Megan D. Hoban,Daniel E. Bauer
View Articletitled, A genome editing primer for the hematologist
Customizing the genome as therapy for the β-hemoglobinopathies
Clinical Trials & Observations
Matthew C. Canver,Stuart H. Orkin
View Articletitled, Customizing the genome as therapy for the β-hemoglobinopathies
The clinical applications of genome editing in HIV
Clinical Trials & Observations
Cathy X. Wang,Paula M. Cannon
View Articletitled, The clinical applications of genome editing in HIV
Ethical and regulatory aspects of genome editing
Clinical Trials & Observations
Donald B. Kohn,Matthew H. Porteus,Andrew M. Scharenberg
View Articletitled, Ethical and regulatory aspects of genome editing

CLINICAL TRIALS AND OBSERVATIONS

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Clinical Trials & Observations
Rachid C. Baz,Thomas G. Martin, III,Hui-Yi Lin,Xiuhua Zhao,Kenneth H. Shain,Hearn J. Cho,Jeffrey L. Wolf,Anuj Mahindra,Ajai Chari,Daniel M. Sullivan,Lisa A. Nardelli,Kenneth Lau,Melissa Alsina,Sundar Jagannath
View Articletitled, Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
Supplemental data
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Clinical Trials & Observations
Philippe Moreau,Cyrille Hulin,Margaret Macro,Denis Caillot,Carine Chaleteix,Murielle Roussel,Laurent Garderet,Bruno Royer,Sabine Brechignac,Mourad Tiab,Mathieu Puyade,Martine Escoffre,Anne-Marie Stoppa,Thierry Facon,Brigitte Pegourie,Driss Chaoui,Arnaud Jaccard,Borhane Slama,Gerald Marit,Karim Laribi,Pascal Godmer,Odile Luycx,Jean-Claude Eisenmann,Olivier Allangba,Mamoun Dib,Carla Araujo,Jean Fontan,Karim Belhadj,Marc Wetterwald,Véronique Dorvaux,Jean-Paul Fermand,Philippe Rodon,Brigitte Kolb,Sylvie Glaisner,Jean-Valere Malfuson,Pascal Lenain,Laetitia Biron,Lucie Planche,Helene Caillon,Herve Avet-Loiseau,Thomas Dejoie,Michel Attal
View Articletitled, VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

IMMUNOBIOLOGY

UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells
Ismael Samudio,Katayoun Rezvani,Hila Shaim,Elyse Hofs,Mor Ngom,Luke Bu,Guoyu Liu,Jason T. C. Lee,Suzan Imren,Vivian Lam,Grace F. T. Poon,Maryam Ghaedi,Fumio Takei,Keith Humphries,William Jia,Gerald Krystal
View Articletitled, UV-inactivated HSV-1 potently activates NK cell killing of leukemic cells
Supplemental data

LYMPHOID NEOPLASIA

MUC1-C drives MYC in multiple myeloma
Ashujit Tagde,Hasan Rajabi,Audrey Bouillez,Maroof Alam,Reddy Gali,Shannon Bailey,Yu-Tzu Tai,Teru Hideshima,Kenneth Anderson,David Avigan,Donald Kufe
View Articletitled, MUC1-C drives MYC in multiple myeloma
Supplemental data
Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia
Aldo M. Roccaro,Antonio Sacco,Jiantao Shi,Marco Chiarini,Adriana Perilla-Glen,Salomon Manier,Siobhan Glavey,Yosra Aljawai,Yuji Mishima,Yawara Kawano,Michele Moschetta,Mick Correll,Ma. Reina Improgo,Jennifer R. Brown,Luisa Imberti,Giuseppe Rossi,Jorge J. Castillo,Steven P. Treon,Matthew L. Freedman,Eliezer M. Van Allen,Winston Hide,Elaine Hiller,Irene Rainville,Irene M. Ghobrial
View Articletitled, Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia
Supplemental data

MYELOID NEOPLASIA

MIP-1α/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice
Tomohisa Baba,Yamato Tanabe,Soichiro Yoshikawa,Yoshinori Yamanishi,Soji Morishita,Norio Komatsu,Hajime Karasuyama,Atsushi Hirao,Naofumi Mukaida
View Articletitled, MIP-1α/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice
Supplemental data

PLATELETS AND THROMBOPOIESIS

Novel phosphatidylethanolamine derivatives accumulate in circulation in hyperlipidemic ApoE−/− mice and activate platelets via TLR2
Sudipta Biswas,Liang Xin,Soumya Panigrahi,Alejandro Zimman,Hua Wang,Valentin P. Yakubenko,Tatiana V. Byzova,Robert G. Salomon,Eugene A. Podrez
View Articletitled, Novel phosphatidylethanolamine derivatives accumulate in circulation in hyperlipidemic <em>ApoE</em><sup><em>−/−</em></sup> mice and activate platelets via TLR2
Supplemental data

THROMBOSIS AND HEMOSTASIS

Role of platelets, neutrophils, and factor XII in spontaneous venous thrombosis in mice
Marco Heestermans,Salam Salloum-Asfar,Daniela Salvatori,El Houari Laghmani,Brenda M. Luken,Sacha S. Zeerleder,Henri M. H. Spronk,Suzanne J. Korporaal,Gerry T. M. Wagenaar,Pieter H. Reitsma,Bart J. M. van Vlijmen
View Articletitled, Role of platelets, neutrophils, and factor XII in spontaneous venous thrombosis in mice
Supplemental data

LETTERS TO BLOOD

Two cases of cyclic neutropenia with acquired CSF3R mutations, with 1 developing AML
Clinical Trials & Observations
Maksim Klimiankou,Sabine Mellor-Heineke,Olga Klimenkova,Elisa Reinel,Murat Uenalan,Siarhei Kandabarau,Julia Skokowa,Karl Welte,Cornelia Zeidler
View Articletitled, Two cases of cyclic neutropenia with acquired <em>CSF3R</em> mutations, with 1 developing AML
Mutations in succinate dehydrogenase B (SDHB) enhance neutrophil survival independent of HIF-1α expression
Robert Jones,Kate E. McDonald,Joseph A. Willson,Bart Ghesquière,David Sammut,Eleni Daniel,Alison J. Harris,Amy Lewis,A. A. Roger Thompson,Rebecca S. Dickinson,Tracie Plant,Fiona Murphy,Pranvera Sadiku,Brian G. Keevil,Peter Carmeliet,Moira K. B. Whyte,John Newell-Price,Sarah R. Walmsley
View Articletitled, Mutations in succinate dehydrogenase B (<em>SDHB</em>) enhance neutrophil survival independent of HIF-1α expression
Supplemental data

BLOOD WORK

Abnormal chromatin clumping in myeloblasts
Leslie Skeith,Adrienne Lee
View Articletitled, Abnormal chromatin clumping in myeloblasts
Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q)
Robin Boutault,Marion Eveillard
View Articletitled, Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q)

ERRATA

Kwok M, Davies N, Agathanggelou A, et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood. 2016;127(5):582-595.
View Articletitled, Kwok M, Davies N, Agathanggelou A, et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in <em>TP53</em>- or <em>ATM</em>-defective chronic lymphocytic leukemia cells. <em>Blood</em>. 2016;127(5):582-595.
DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7):829-838.
View Articletitled, DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. <em>Blood.</em> 2016;127(7):829-838.
All Issues

Advertisement intended for health care professionals

Licking the wound with procoagulant vesicles
Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study
CAR T-cells in autoimmunity: game changer or stepping stone?
Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH
How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals